The mitogen-activated protein kinase (MAP kinase) is a key participant in growth factor-stimulated intracellular events such as proliferation and differentiation. We and others have previously described a cross-talk between the MAP kinase pathway and the cAMP pathway. Indeed, in several cell lines and, in particular in fibroblasts, an increase in the level of cAMP produced an inhibition of MAP kinase together with decreased cell proliferation. In contrast, in PC12 cells, cAMP induced an increase in the NGF-induced activation of MAP kinase concomitantly with augmented NGF-induced differentiation. Therefore, it has been proposed that the cellular context is important for the nature of the cAMP effects on growth factor-stimulated MAP kinase activity. Here we show that the type of tyrosine kinase receptor stimulated also participates in the nature of the cAMP effect. Thus, in NIH3T3 fibroblasts expressing NGF receptors (NIH3T3/trk cells) we found that cAMP potentiates NGF-stimulated ERK1 and MEK1 activities, whereas in NIH3T3 fibroblasts expressing insulin receptors (NIH3T3/IR cells) we saw no effect of cAMP on the activation of insulin-stimulated ERK1 and MEK1. In PC12 cells and in Rat1 fibroblasts expressing insulin receptors (PC12/IR and Rat1/IR cells) we observed, respectively, a potentiation and an inhibition of insulinstimulated ERK1 activity. In addition, cAMP does not seem to modify the basal nor growth factor-stimulated Shc or IRS-1 tyrosine phosphorylation in the different cell lines studied. Finally, we observed that cAMP inhibited serum-and insulin-induced, but not NGF-induced, cell proliferation in NIH3T3 cells. However, cAMP potentiated insulin-stimulated cell differentiation in PC12/IR cells. These results led us to conclude that the cAMP effect on cell proliferation in NIH3T3 fibroblasts and PC12/IR cells appears to be correlated, in part, with the effect of cAMP on the MAP kinase pathway, but by itself this pathway cannot fully account for these observations. (Endocrinology 138: 1111-1120, 1997) L IGAND BINDING to tyrosine kinase receptors leads to receptor autophosphorylation on several tyrosine residues, and to phosphorylation of cellular substrates. For most receptors, autophosphorylation creates docking sites for proteins containing SH2 (Src Homology 2) domains, such as Shc (Src homology collagen), PI 3-K (phosphatidylinositol 3-kinase), or PLC␥ (phospholipase C␥) leading to the formation of multicomponent signaling complexes (1). The insulin receptor and the IGF-1 receptor autophosphorylate but use mainly IRS-like (insulin receptor substrate-like) proteins as docking molecules. These phosphorylated IRS-like proteins, IRS-1, IRS-2 and Gab-1, bind to several SH2 domain-containing proteins (2, 3). Phosphorylated Shc and IRS-1 are both able to interact with Grb2 (growth factor receptor-bound protein 2), a docking molecule composed of one SH2 and two SH3 domains (4, 5). Grb2 is constitutively associated with the guanine nucleotide exchange factor Sos (Son of sevenless), which promotes the exchange of Ras-GDP (inactive) to Ras-GTP (active) (6). Therefore, Grb2 associated with Shc or IRS-1 allows the recruitment of the complex to the cell membrane, where Ras is localized. Activated Ras is then able to associate and activate, by a poorly understood mechanism, the serine/ threonine kinase Raf 1 (7-9). Raf 1 is a member of the family of mitogen-activated protein kinase-kinase (MAPKK) kinases that activate MAPK kinases or MEKs; MEK1 and MEK2, (MAP kinase/ERK Kinases), by a double serine phosphorylation (10 -12). MEKs are dual specific kinases (13-16), which in turn activate MAP kinases by phosphorylation on both threonine and tyrosine (17, 18) . The MAP kinases, p44
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MAPK and p42
MAPK
, also named extracellular-signal regulated kinases (ERK1 and 2 respectively), are serine/threonine protein kinases, which have been implicated in many cellular responses to growth factors. Numerous signaling molecules are activators of the MAP kinase cascade. These include, in addition to the tyrosine kinase receptors (19 -21) , phorbol esters such as PMA (22) , which stimulate protein kinase C (PKC) and ligands for the serpentine receptors, such as thrombin which acts through G proteins (23) .
Previous studies have demonstrated a cross-talk between the MAP kinase pathway and the cAMP signaling pathway. It has been shown that cAMP attenuated tyrosine kinase receptor-stimulated MAP kinase in cells such as smooth muscle cells treated with PDGF BB (24) , fibroblasts stimulated by EGF, LPA (25) (26) (27) , PDGF, or insulin (28) and adi-pocytes stimulated by insulin (29) . This inhibitory action occurs concomitantly with a decrease in the biological effects induced by these receptors. This inhibition appears to be mediated by protein kinase A (PKA). Indeed, PKA was shown to phosphorylate Raf 1, inducing a decrease in the association between Ras and Raf 1, which leads to a reduced Raf 1 activity (25, 27) .
In contrast to all other systems, we have previously shown that in PC12 cells an elevation in intracellular cAMP increased in a more than additive manner the effects of NGF, IGF-I and PMA on ERK1 and MEK1 activities. Further, cAMP increased by 3-fold NGF-stimulated neurite formation in this cell line (30) . Surprisingly, the activity of B-Raf, the predominant isoform of Raf in PC12 cells, was inhibited. Like in other cell types, the phosphorylation of B-Raf by PKA was responsible for reducing its ability to associate with Ras, resulting in a decrease in its activity (31) . Hence, the mechanism(s) by which cAMP potentiated growth factor-stimulated MAP kinase in PC12 cells remains unknown. The differences between the cAMP effect on ERK1 activity in NGF-stimulated PC12 cells compared to its effect in other cell types (i.e. potentiation vs. inhibition) could be due to the PC12 cell context per se. Alternatively, it could result, at least in part, from the nature of the tyrosine kinase receptors.
To approach this issue, we studied the effects of overexpression of NGF receptors in a cellular context different from that of PC12 cells, i.e. NIH3T3 cells (NIH3T3/trk). Conversely, we used PC12 cells expressing insulin receptors (PC12/IR cells) (32) . Finally, we looked at NIH3T3 cells and Rat1 cells overexpressing the insulin receptor (NIH3T3/IR, Rat1/IR respectively) to compare the cAMP effect on the insulin-stimulated MAP kinase pathway in different cells. In this series of cell lines we looked at the cAMP effect on: 1) ERK1 and MEK1 activities; 2) Shc and IRS-1 tyrosine phosphorylation; and 3) cell growth and differentiation.
Materials and Methods Antibodies
Peptides corresponding to amino acids 356 -367 of rat ERK1 (TAR-FQPGAPEAP), and to the 17 N-terminal amino acids of human MEK1 (PKKKPTPIQLNPAPDGS) were synthesized by Neosystem (Strasbourg, France). The peptides were coupled to keyhole limpet hemocyanin and used to generate rabbit polyclonal antisera (30) .
The anti-IRS-1 antibody is a rabbit polyclonal antiserum directed against the 14 C-terminal amino acids of IRS-1 (CASINFQKQPEDRQ) (33) . The mouse monoclonal antiphosphotyrosine antibody (clone 4G10), and the rabbit anti-Shc polyclonal antibody raised against amino acids 366 -473 of a recombinant fusion protein Shc-SH2 coupled to GST, were purchased from UBI (Lake Placid, NY).
Materials
Sodium orthovanadate, BSA, leupeptin, phenylmethylsulfonyl fluoride (PMSF), myelin basic protein (MBP) from bovine brain, protein A-sepharose, Triton X-100, 8-(4-chlorophenylthio)-cAMP (CPT), forskolin were purchased from Sigma (St. Louis, Ml 
Immunoprecipitation of ERK1 or MEK1 activated in intact cells
All cell lines were plated into 12-well dishes for ERK1 or MEK1 assays. Following starvation, the cells were incubated for various times with the indicated effectors. The cells were washed twice with stop buffer (50 mm HEPES, pH 7.5, 150 mm NaCl, 10 mm Na 4 P 2 O 7 , 2 mm Na 3 VO 4 , 100 mm NaF) and solubilized for 15 min at 4 C in the same buffer containing 1% (vol/vol) Triton X-100, 100 U/ml aprotinin, 20 m leupeptin and 0.2 mg/ml PMSF (solubilization buffer). The cell lysates were clarified by centrifugation at 18,000 ϫ g for 15 min at 4 C and then incubated for 2 h at 4 C with antibodies to ERK1 or MEK1 preabsorbed on protein A-Sepharose beads. Pellets were then washed three times with the solubilization buffer.
ERK1 activity
Pellets containing immunoprecipitated ERK1 were washed twice with 50 mm HEPES, 150 mm NaCl, 10% (vol/vol) glycerol, 0.1% (vol/ vol) Triton X-100, 0.2 mm Na 3 VO 4 . They were resuspended in 50 l of the same buffer containing 100 units/ml aprotinin, 20 m leupeptin, and 0.2 mg/ml PMSF. Phosphorylation of MBP was initiated by addition of 150 g/ml MBP, 10 mm Mg acetate, 1 mm dithiothreitol (DTT), and [␥-
32 P]ATP (5 m, 33 Ci/mmol). The phosphorylation reaction was allowed to proceed for 30 min at room temperature and stopped by spotting 50 l onto Whatman P-81 filter papers which were then dropped into 1% (vol/vol) orthophosphoric acid. The papers were washed several times, rinsed once in ethanol, air dried, and the radioactivity was determined by Cerenkov-counting. Background values obtained from a mixture lacking cell lysate were subtracted from all values.
MEK1 activity
Immunoprecipitated MEK1 activity was measured by an in vitro reconstitution assay using recombinant rat ERK1 (11, 37) and MBP. Briefly, pellets containing immunoprecipitated MEK1 were washed twice in 50 mm HEPES, pH 7.4, and resuspended with 50 ml of 50 mm HEPES, 100 U/ml aprotinin, 20 mm leupeptin, 0.2 mg/ml PMSF pH 7.4, containing 1 g of recombinant rat ERK1. The phosphorylation cascade was initiated by addition of [␥-
32 P]ATP (50 m, 50 Ci/mmol), 150 g/ml MBP, 15 mm MgCl 2 , 2 mm EGTA. The phosphorylation reaction was allowed to proceed for 20 min at room temperature and was stopped as described above for the ERK1 assay. The background consisting of all reagents except for cell lysate was subtracted from all values.
Tyrosine phosphorylation of Shc and IRS-1
The cells were plated into 6-well dishes for phosphorylation assay of Shc and IRS-1. After stimulation by the indicated agonists the cells were solubilized as described above. Lysates were incubated for 4 h with pellets of protein A-sepharose coupled to anti-IRS-1 antibody or anti-Shc antibody. The pellets were washed three times with 50 mm HEPES, 150 mm NaCl, 0.1% (vol/vol) Triton X-100 and resuspended in Laemmli sample buffer (3% (wt/vol) SDS, 70 mm Tris, 11% (vol/vol) glycerol) containing bromophenol blue (0.05%) and ␤-mercaptoethanol 0.05% (vol/vol). The proteins were separated on SDS/PAGE using a 7.5% resolving gel. The proteins were then transferred to polyvinyliden difluoride (PVDF) membranes. The membranes were incubated in blocking buffer (10 mm Tris, 140 mm NaCl/5% (wt/vol) BSA) for 2 h at 22 C, then overnight at 4 C with the mouse antiphosphotyrosine antibodies. The membranes were washed several times for 1 h with 10 mm Tris, 140 mm NaCl/0.5% (vol/vol) NP40 and were incubated with rabbit antimouse antibody for 1 h. After further washing for 45 min, the membranes were incubated for 1 h at 22 C with [ 125 I] conjugated protein A (5 ϫ 10 5 cpm/ml in blocking buffer) and then washed again. The tyrosine-phosphorylated proteins were visualized by autoradiography.
In some experiments, the tyrosine-phosphorylated Shc proteins from treated or untreated cells were immunoprecipitated by the antiphosphotyrosine antibody and revealed by Western blotting with the antiShc antibody.
Cell proliferation in NIH3T3 fibroblasts and differentiation in PC12/IR cells
NIH3T3/trk and NIH3T3/IR cells were plated into 6-well dishes and PC12/IR cells in collagen coated 6-well dishes at a density of 40,000 cells per well. After 2 days, the cells were starved for 48 h and then stimulated by NGF (100 ng/ml), insulin (10 Ϫ7 m), serum (10%), forskolin (10 Ϫ5 m) or CPT-cAMP (1 mm) alone or in combination as indicated. The NIH3T3 cells were counted 4 days after stimulation and the PC12/IR cells were photographed after 48-h stimulation.
Results
To approach the relative contributions of the cellular environment and of the receptor type in the cAMP-effect on the MAP kinase pathway, we used different cell lines overexpressing the NGF receptor (NIH3T3/trk) or the insulin receptor (NIH3T3/IR, Rat1/IR, and PC12/IR). We studied ERK1 and MEK1 activation, and Shc and IRS-1 tyrosine phosphorylation. The agonists used to increase the level of intracellular cAMP were CPT-cAMP, which is a permeable and nonmetabolizable analog of cAMP, and forskolin, which directly activates adenylate cyclase.
Effect of cAMP on insulin-or NGF-stimulated ERK1 and MEK1 activities
NIH3T3/trk cells were stimulated by NGF for different periods of time in the presence or absence of forskolin. As shown in Fig. 1A , NGF stimulation of ERK1 was rapid, with a maximal effect at 5 min (2.2-fold), and was sustained for at least 1 h. Forskolin alone had no effect on ERK1 activity. When NGF and forskolin were added together, ERK1 activity was enhanced at 5 and 10 min compared with the effect of NGF alone (3.2-fold). Thus, increasing the intracellular cAMP level results in potentiation of NGF-stimulated ERK1 activity in NIH3T3 fibroblasts expressing NGF receptors.
We next looked at MEK1. After stimulation of the cells by the ligands for increasing periods of time, MEK1 was immunoprecipitated and recombinant ERK1 was added as a substrate. Activation of recombinant ERK1 was then detected by incorporation of radiolabeled P i into MBP. As shown in Fig. 1B , a transient stimulation of MEK1 by NGF was observed with a maximum at 5 min and a decrease at 15 min. However, in contrast to MAP kinase we observed a slight increase from 15 min up to 1 h probably due to a difference in regulation of both enzymes. The forskolin effect on MEK1 activity was similar to that observed on ERK1, i.e. forskolin alone had no effect, but forskolin plus NGF enhanced the NGF action. We conclude that in NIH3T3 cells expressing the NGF receptor, forskolin potentiates the NGF effect on both MEK1 and ERK1.
In NIH3T3/IR cells, insulin-stimulation of ERK1 was transient with a peak at 5 min (2.4-fold) ( Fig. 2A) . At later times a sustained activity of approximately 25% of maximum was observed until at least 1 h. Interestingly, forskolin did not alter the effect of insulin on ERK1 activity (2.5-fold). Similarly to the findings with ERK1, we observed that MEK1 (Fig. 2B) was transiently stimulated by insulin with a peak at 5 min; the activity decreased at 15 min and was followed by a sustained activation of approximately 30% of maximum until at least 1 h. Forskolin alone did not stimulate MEK1, and addition of forskolin to insulin did not modify the insulinstimulated MEK1 activity. Taken together our results indicate that in NIH3T3 cells the cAMP effect on ERK1 and MEK1 vary depending on the type of stimulated tyrosine kinase receptor, i.e. the NGF receptor vs. the insulin receptor.
In PC12/IR cells (Fig. 3A) , insulin stimulation of ERK1 was transient with a maximum at 5 min (8-fold). When CPTcAMP and insulin were added together, ERK1 activation was increased at each time point (12-fold at 5 min). CPT-cAMP alone induces a slight ERK1 activation (2-fold). The stimulation of MEK1 correlated with that of ERK1 because it was transient with a maximum between 2 and 5 min, and potentiated by CPT-cAMP (Fig. 3B) .
We next studied the effect of a cAMP increase in Rat1 fibroblasts overexpressing the insulin receptor (Rat1/IR). As shown in Fig. 4A , insulin induced a sustained ERK1 activation with a maximum at 5 min (5-fold) and lasting 1 h. Forskolin induced a complete inhibition of ERK1. Concerning MEK1 (Fig. 4B) , the inhibition induced by forskolin had a similar time-course as that obtained with ERK1.
In conclusion, the cellular context appears to have an important impact on the nature of the cAMP effect. Indeed, the cAMP action on the MAP kinase cascade varied depending on the cells in which the insulin receptor is activated. Further, the nature of the receptor itself (NGF vs. insulin) seems also to be important, because in a same cell context (NIH3T3 fibroblasts), cAMP affects differently the MAP kinase cascade.
Effect of cAMP on PDGF-stimulated ERK1 activity in NIH3T3/trk and NIH3T3/IR cells
To verify that the difference in the cAMP effect on MAP kinase between NIH3T3/trk and NIH3T3/IR cells did not stem from a clonal variation, we studied the cAMP effect on an endogenous receptor tyrosine kinase expressed in both cell lines, the PDGF receptor. NIH3T3/trk cells and NIH3T3/IR cells were stimulated for 5 min by PDGF in absence or presence of forskolin, and then ERK1 activity was measured. In both cell lines, forskolin had no effect on the maximal ERK1 activity stimulated by PDGF (Fig. 5) . 
Effect of cAMP on tyrosine phosphorylation of Shc
Once phosphorylated by a tyrosine kinase receptor, both Shc and IRS-1 are able to bind the complex Grb2-Sos, leading to Ras activation and consequently stimulation of the MAP kinase cascade. Therefore, we searched for a possible modulation in tyrosine phosphorylation of these proteins by cAMP agonists. Tyrosine phosphorylation of Shc was measured after treatment of cells by effectors for the indicated time periods. In some experiments the tyrosine-phosphorylated Shc was immunoprecipitated from the cell lysates using an anti-phosphotyrosine antibody (Fig. 6, A, B, and D) . Immunoprecipitated proteins were then separated by polyacrylamide gel electrophoresis, and after transfer, immunoblotted with anti-Shc antibodies. In panel C, Shc was immunoprecipitated using an anti-Shc antibody, and its phosphorylation was visualized by blotting with an antiphosphotyrosine antibody.
In all the cell lines studied, two proteins were found which corresponded to the p52 Shc Shc was increased by NGF (A) or insulin (B-D) treatment. Forskolin alone had no effect on Shc tyrosine phosphorylation. Further, addition of forskolin or CPT-cAMP in combination with NGF or insulin did not modify the growth factorinduced tyrosine phosphorylation of Shc. This suggests that the inhibition or potentiation of ERK1 and MEK1 activities due to cAMP did not occur at the Shc level.
Effect of cAMP on tyrosine phosphorylation of IRS-1
IRS-1 tyrosine phosphorylation was studied only in cells overexpressing insulin receptors: PC12/IR, NIH3T3/IR and Rat1/IR cells (Fig. 7 , A-C, respectively). After stimulation of the cells, IRS-1 was immunoprecipitated and tyrosine phosphorylation was revealed by immunoblotting with an antiphosphotyrosine antibody. In each cell line studied, tyrosine phosphorylation of IRS-1 was maximal at 5 min. It was persistant for at least 1 h in NIH3T3/IR and Rat1/IR cells, but decreased at 30 min in PC12 cells. CPT-cAMP (A) or forskolin (B, C) did not modify IRS-1 tyrosine phosphorylation, and did not alter the insulin effect except in Rat1/IR cells (C). In these cells (C), addition of forskolin to insulin induced a slight, but significant, decrease in IRS-1 tyrosine phosphorylation at 10 min (20%, P Յ 0.025, n ϭ 4).
Effect of cAMP on NIH3T3 cells proliferation and on PC12/ IR cells differentiation
To determine whether the effect of cAMP on MEK1 and ERK1 could be of physiological relevance, we studied the effect of cAMP-elevating agents on cell growth in NIH3T3 cells and on cell differentiation in PC12/IR cells. To search for a cAMP effect on cell growth, cells were plated into six-well dishes, starved for 48 h, and then stimulated by the indicated effectors. The cells were counted 4 days after stimulation as described in the Methods section. As shown in Table 1 , in NIH3T3/trk cells, forskolin did not stimulate cell proliferation. Serum-stimulation, taken as a control, induced a 6-fold increase in proliferation (this value correspond to our 100% proliferation). When forskolin was added to serum we observed a 30% inhibition. NGF-stimulation induced an increase in proliferation (2-to 3-fold) after 4 days that was not modified by addition of forskolin. In NIH3T3/IR cells, after 4 days serum led to an approximately 10-fold stimulation (our 100% proliferation) and forskolin decreased the serumstimulated proliferation by approximately 40%. Insulin stimulated cellular proliferation (3-fold), and we found an inhibition of approximately 35% by concomitant addition of forskolin to insulin.
Stimulation of PC12/IR cells by insulin induces cell differentiation (32) (fig. 8C ). Therefore, we looked at the effect of CPT-cAMP on insulin-induced differentiation of PC12/IR cells. CPT-cAMP alone was able to produce cell differentiation. However, the neurite size was less important than with insulin stimulation (Fig. 8B) . When CPT-cAMP was added to insulin we observed an increase in the number of differentiated cells and in the length of the neurites compared with insulin alone (Fig. 8D) .
Discussion
In this report we compared, in different cell systems, the cAMP effect on ERK1 and MEK1 stimulated by NGF and insulin. We also studied early steps of insulin and NGF signaling, such as IRS-1 and Shc tyrosine phosphorylation. Finally, the effect of cAMP on proliferation of NIH3T3 cells and differentiation of PC12/IR cells was investigated. The results are summarized in Table 2 .
We show that in NIH3T3/trk fibroblasts, forskolin potentiated the NGF-stimulated ERK1 and MEK1 activities. In contrast, in NIH3T3/IR cells cAMP had no effect on the insulin-stimulated ERK1 and MEK1. This difference between the two cell lines was also observed using CPT-cAMP or other agents which raise cAMP (cholera toxin, IBMX) (data not shown). Moreover, it does not stem from clonal variation between NIH3T3/trk and NIH3T3/IR cells because both cell lines gave similar results, i.e. no effect of cAMP on the PDGFinduced ERK1 stimulation. Further, despite a difference in receptor number (10 5 NGF receptors/cell in NIH3T3/trk cells vs. 10 6 receptors/cell in NIH3T3/IR cells), stimulation by NGF is sufficient to maximally activate the MAP kinase (2.2-fold) in a manner similar to the insulin receptor (2.4-fold). Dose-response experiments showed that the peptide concentrations used in our work (100 ng/ml NGF and 10 Ϫ7 m insulin) induced a maximal effect. Moreover, we found that at each growth factor concentration cAMP was without effect on insulin action, whereas it potentiated NGF action. In conclusion, the differences in the cAMP effect on MAP kinase is likely to be a consequence of qualitative differences between NGF and insulin signaling. Hence, our results indicate that in a given cell system regulation of the MAP kinase pathway by cAMP depends, at least in part, on which tyrosine kinase receptor is activated.
In Rat1/IR cells, cAMP produced a total inhibition of insulin-stimulated ERK1 and MEK1. These data are in accordance with previous published observations in Rat1 fibroblasts exposed to EGF, LPA (25) (26) (27) , or PDGF (28) . In PC12/IR cells, we found an increase in insulin-stimulated ERK1 and MEK1 after treatment by CPT-cAMP. This is similar to our previous work in native PC12 cells stimulated by NGF and other effectors (30) . Recently, we also reported a comparable potentiating effect of cAMP on glucose-activated ERK1 in pancreatic ␤-cells (38) . Likewise, another group showed an additive effect of cAMP on IGF-1-stimulated MAP kinase activity in primary cultures of pars tuberalis cells (39) . Our observations in NIH3T3/IR cells are at variance with those obtained by Burgering et al., who found an inhibition of ERK2 by a cAMP-elevating agent after stimulation by EGF and insulin in NIH3T3 expressing insulin receptors (A14 cells) (28) . The reason for this discrepancy is not clear but could be explained by differences between the cell lines. This reinforces the notion attributing an important role of the cell context in the cAMP actions on the MAP kinase cascade.
To look for a putative target regulated by cAMP, we studied tyrosine phosphorylation of Shc and IRS-1. Generally speaking, in our cell lines treatment by a cAMP agonist had no effect on the basal or growth factor-stimulated tyrosine phosphorylation of Shc and IRS1. In Rat1 cells, phosphorylation of IRS-1 was decreased at 10 min; however, this decrease did not appear to be correlated with the total inhibition of ERK1 observed in Fig. 4A . Taking our observations together, we conclude therefore that in our cell lines the target for cAMP is likely to be located downstream of Shc and IRS-1 in the MAP kinase pathway, or on a parallel pathway that could impinge on MEK1 and ERK1. The MAP kinase cascade has been shown to be inhibited by increased cAMP levels in several cell systems such as PDGF-stimulated smooth muscle cells (24) , and insulin-stimulated adipocytes (29) . However, the mechanism by which cAMP inhibits the MAP kinase pathway is only partially known (25) (26) (27) (28) 40) . It has been suggested that the cAMP-dependent protein kinase (PKA) could decrease the interaction between Ras and Raf, which is the first functional module of the MAP kinase cascade. The small G protein Rap has been proposed as a potential molecule responsible for such an inhibition because it has been described as acting upstream of Raf and MEK, and downstream of Ras in Rat1 cells (41) . In addition, it is phosphorylated by PKA in vitro and in vivo (42, 43) . Rap would compete with Ras for the interaction with Raf 1, but in contrast to Ras it would not be able to activate Raf 1 (24) . Moreover, PKA phosphorylates Raf 1 itself, thereby inhibiting its interaction with Ras and hence its kinase activity (44) . We and others also found that cAMP inhibited B-Raf, the major Raf isoform in PC12 cells, and this despite its potentiating effect on NGF-stimulated ERK1 activity in these cells (31, 45) .
The mechanism(s) underlying the potentiating effect of cAMP on MAP kinase is (are) still unknown. One simple explanation could be that, in some cell lines, growth factors could activate, in addition to Raf, an unidentified MEK kinase which would be positively modulated by PKA. This MEK kinase could be present in PC12 cells, NIH3T3/trk and NIH3T3/IR cells, but absent in Rat1 fibroblasts or other systems where cAMP does not stimulate the ERK1. Several MEK activators different from Raf or MEKK (46) have been cloned recently (47-49), but the effect of PKA or cAMP on these MEK activators has not been evaluated so far. It is also possible that the MAP kinase activity could be regulated by cAMP through a signaling pathway triggered by tyrosine kinase receptors such as PI 3-K or PLC ␥. This mechanism could explain the difference between NIH3T3/trk and NIH3T3/IR if we consider that each tyrosine kinase receptor could interact and/or activate the different mediators implicated in signaling with a specific strength and time course. Accordingly, it has been described that trkA and EGF receptors have a distinct affinity for PLC ␥ that could account for a differential effect of growth factors on MAP kinase activation and on biological effects such as transformation of fibroblasts (50). Therefore, the differential activation by insulin receptors and trkA of a given set of molecules implicated in intracellular signaling and submitted or not to reg- ulation by cAMP could explain the different effects of cAMP on the MAP kinase cascade.
We next investigated whether the cAMP modulation of the MAP kinase pathway could be correlated with changes in biological responses such as cellular proliferation in NIH3T3 fibroblasts or differentiation in PC12/IR cells. Results from fibroblasts showed a slight induction of cell proliferation by insulin or NGF (approximately 30 -40% of serum stimulation) that was not modified by addition of forskolin in NIH3T3/trk cells but diminished by 35% in NIH3T3/IR cells. In PC12/IR cells, stimulation with insulin induced a slow growth of dendritic processes after 24 h that was accelerated by addition of CPT-cAMP, as was recently described by our group for NGF (30) . Thus, the cAMP effect on proliferation does not correlate with its effect on MAP kinase. Thus, we conclude that the MAP kinase pathway by itself cannot fully account for the biological effect induced by cAMP. Both cell lines were plated in 6-well dishes at a density of 40,000 cells per well. Two days later, the cells were starved during 48 h and then treated with NGF (100 ng/ml), insulin (10 Ϫ7 M), forskolin (10 Ϫ5 M), or serum (10%) alone or in combination as indicated. The cells were then counted after 4 days. We show two separate experiments (a and b) performed in triplicate. The results are expressed as a percentage of the value in the presence of serum. The SD are Ͻ10% in each condition. The percent of cAMP-inhibition in each condition is also indicated.
shown to be crucial for the cell cycle progression through the G1 phase (54). In contrast to p90
S6k , p70 S6k is considered to be the major physiological S6 kinase in mammalian cells and is not activated by MAP kinase. Phosphorylation of the ribosomal protein S6 by p70 S6k increases protein synthesis, which is essential for induction of cellular proliferation by growth factors (for review see Ref. 55). Our hypothesis is supported by the observation that treatment of lymphoid cells by agents increasing intracellular cAMP levels inhibited IL2-induced activation of p70 S6k , and concomitantly cellular proliferation without affecting the MAP kinase cascade (56) (for a review see Ref. 57). We could imagine that cAMP affects cell proliferation and differentiation by a concomitant action on the MAP kinase cascade and on the p70 s6k pathway. Another possibility to explain the cAMP effect on cell growth could be that cAMP acts directly on the cell cycle, through G1 cyclins and their associated cyclin-dependent kinases (cdks), which are responsible for progression in the G1 phase. It has been reported that cAMP induced G1 phase arrest in CSF-1-stimulated macrophages through p27 Kip1 , which is an inhibitor of the cyclin-dependent kinase 4. cAMP has been found to increase the level of p27
Kip1 leading to saturation of the complex cyclin D-cdk4 by p27 Kip1 , and thus preventing phosphorylation of the complex by the cdk-activating kinase (CAK) (58).
In summary, the present study further illustrates that specificity in signaling by tyrosine kinase receptors and a given final biological response are generated by a complex interplay between the intracellular content and agents to which the cells are exposed. 
